X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (660) 660
humans (560) 560
cell biology (316) 316
animals (290) 290
phosphorylation (252) 252
cell cycle (249) 249
cancer (237) 237
cell line, tumor (219) 219
cell cycle proteins - metabolism (214) 214
oncology (210) 210
dna damage (204) 204
protein-serine-threonine kinases - metabolism (201) 201
polo-like kinase-1 (199) 199
apoptosis (196) 196
mitosis (186) 186
biochemistry & molecular biology (178) 178
proteins (160) 160
kinases (137) 137
checkpoint (131) 131
mice (127) 127
proto-oncogene proteins - metabolism (121) 121
research (113) 113
signal transduction (112) 112
cell cycle proteins - genetics (111) 111
checkpoint kinase 1 (102) 102
female (101) 101
apoptosis - drug effects (100) 100
protein-serine-threonine kinases - genetics (98) 98
biology (97) 97
protein kinases - metabolism (95) 95
cell division (87) 87
hela cells (86) 86
cell cycle checkpoints - drug effects (85) 85
plk1 (85) 85
article (82) 82
dna (82) 82
dna repair (82) 82
genetic aspects (79) 79
antineoplastic agents - pharmacology (78) 78
dna-damage (76) 76
activation (75) 75
genetics & heredity (75) 75
cell-cycle (74) 74
dna-damage checkpoint (73) 73
cell proliferation - drug effects (71) 71
expression (71) 71
protein kinase inhibitors - pharmacology (71) 71
research article (69) 69
protein-serine-threonine kinases - antagonists & inhibitors (67) 67
analysis (66) 66
p53 (66) 66
chk1 (65) 65
cell cycle proteins - antagonists & inhibitors (63) 63
physiological aspects (63) 63
biological phenomena, cell phenomena, and immunity (61) 61
multidisciplinary sciences (61) 61
spindle assembly checkpoint (61) 61
cell proliferation (60) 60
deoxyribonucleic acid--dna (60) 60
tumor suppressor protein p53 - metabolism (60) 60
gene expression (59) 59
rna interference (57) 57
binding (56) 56
cell line (56) 56
cycle (56) 56
protein-kinase (56) 56
cells (54) 54
health aspects (53) 53
mitosis - drug effects (53) 53
tumors (53) 53
proto-oncogene proteins - genetics (52) 52
signal transduction - drug effects (51) 51
polo-like kinase (49) 49
double-strand breaks (48) 48
medicine (48) 48
proto-oncogene proteins - antagonists & inhibitors (48) 48
science (48) 48
cancer-cells (47) 47
male (47) 47
biochemistry (45) 45
chemotherapy (45) 45
inhibition (45) 45
mutation (45) 45
review (45) 45
chromosomes (44) 44
neoplasms - genetics (44) 44
nuclear proteins - metabolism (44) 44
protein binding (44) 44
cell (42) 42
cell survival - drug effects (42) 42
phosphotransferases (42) 42
protein (42) 42
calcium (41) 41
cdc2 protein kinase - metabolism (41) 41
cell death (41) 41
dna replication (41) 41
ionizing-radiation (41) 41
models, biological (41) 41
pharmacology & pharmacy (41) 41
polo-like kinase 1 (41) 41
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cell Cycle, ISSN 1538-4101, 10/2010, Volume 9, Issue 20, pp. 4200 - 4212
PLK1 is a critical mediator of G2/M cell cycle transition that is inactivated and depleted as part of the DNA damage-induced G2/M checkpoint. Here we show that... 
Proteins | Binding | Landes | Calcium | Biology | Bioscience | Cell | Cycle | Organogenesis | Cancer | Repression | DNA damage response | PLK1 | p53 | APOPTOSIS | ACTIVATION | DNA-DAMAGE | TRANSCRIPTIONAL REPRESSION | DOWN-REGULATION | DEPLETION | HUMAN CANCER-CELLS | MAMMALIAN-CELLS | CELL BIOLOGY | GENE-EXPRESSION | repression | P53 TUMOR-SUPPRESSOR | G/M checkpoint | Humans | Piperazines - metabolism | Tumor Suppressor Protein p53 - genetics | Cell Cycle Proteins - antagonists & inhibitors | Cyclin-Dependent Kinase Inhibitor p21 - genetics | RNA Interference | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Cycle Proteins - genetics | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Transcription, Genetic | Hydroxamic Acids - pharmacology | Genes, Reporter | Protein-Serine-Threonine Kinases - metabolism | Imidazoles - metabolism | Proto-Oncogene Proteins - metabolism | Promoter Regions, Genetic | Proto-Oncogene Proteins - antagonists & inhibitors | Down-Regulation | Cell Cycle Proteins - metabolism | Protein-Serine-Threonine Kinases - genetics | Tumor Suppressor Protein p53 - metabolism | Proto-Oncogene Proteins - genetics | Gene Expression Regulation - drug effects | Animals | Cell Cycle - physiology | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | DNA Damage | Apoptosis | Index Medicus | Report | M checkpoint | G2
Journal Article
BMB Reports, ISSN 1976-6696, 2014, Volume 47, Issue 5, pp. 249 - 255
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2014, Volume 9, Issue 5, pp. e94298 - e94298
Journal Article
Journal Article
Cell Cycle, ISSN 1538-4101, 07/2014, Volume 13, Issue 14, pp. 2237 - 2247
Polo-like kinases (PLKs) and Aurora kinases (AKs) act as key cell cycle regulators in healthy human cells. In cancer, these protein kinases are often... 
Aurora kinases | MEK/ERK/mTORC1 | cell cycle | PI3K/Akt/mTORC2 | apoptosis | polo-like kinases | T-ALL | caspases | Polo-like kinases | Cell cycle | Caspases | Apoptosis | MAMMALIAN TARGET | RAPAMYCIN | ACUTE MYELOID-LEUKEMIA | ONCOGENIC TRANSFORMATION | CYTOTOXIC ACTIVITY | CANCER | CELL BIOLOGY | 1 PLK1 | PATHWAY | RESISTANCE | INHIBITOR BI 2536 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Aurora Kinase B - metabolism | Apoptosis - drug effects | Coculture Techniques | Humans | Aza Compounds - pharmacology | Aurora Kinase A - antagonists & inhibitors | Molecular Targeted Therapy | Aurora Kinase A - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Cell Cycle Proteins - antagonists & inhibitors | Dose-Response Relationship, Drug | G2 Phase Cell Cycle Checkpoints - drug effects | Drug Design | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Tumor Cells, Cultured | Aurora Kinase B - antagonists & inhibitors | Protein-Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins - metabolism | Cell Survival - drug effects | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Proto-Oncogene Proteins - antagonists & inhibitors | Jurkat Cells | Cell Cycle Proteins - metabolism | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - enzymology | Drug Synergism | Animals | Signal Transduction - drug effects | Cyclohexanecarboxylic Acids - pharmacology | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Index Medicus | Report | Akt | MEK | PI3K | mTORC2 | mTORC1 | ERK
Journal Article
Pigment Cell & Melanoma Research, ISSN 1755-1471, 03/2012, Volume 25, Issue 2, pp. 259 - 274
Resistance to therapies develops rapidly for melanoma leading to more aggressive disease. Therefore, agents are needed that specifically inhibit proteins or... 
V600E | SKI‐I | proliferation | PRAS40 | AKT3 | melanoma | apoptosis | sphingosine kinase‐1 | tumorigenesis | S‐1‐P | B‐RAF | Melanoma | Sphingosine kinase-1 | SKI-I | Tumorigenesis | B-RAF | Proliferation | S-1-P | Apoptosis | CANCER-CELLS | SURVIVAL | sphingosine kinase-1 | MALIGNANT-MELANOMA | CELL BIOLOGY | DERMATOLOGY | METASTATIC MELANOMA | V600EB-RAF | ONCOLOGY | THERAPEUTIC TARGET | CASPASE ACTIVATION | SIGNALING CASCADE | 1-PHOSPHATE | Cyclin D1 - metabolism | Lysophospholipids - metabolism | Skin Neoplasms - drug therapy | Apoptosis - drug effects | Humans | Melanoma - enzymology | Molecular Targeted Therapy | Skin Neoplasms - enzymology | Melanocytes - drug effects | Melanocytes - pathology | Sphingosine - metabolism | Proto-Oncogene Proteins c-akt - metabolism | Skin Neoplasms - pathology | Cell Survival - drug effects | Melanoma - pathology | Cell Adhesion - drug effects | Down-Regulation - drug effects | Fibroblasts - pathology | Phosphotransferases (Alcohol Group Acceptor) - metabolism | Up-Regulation - drug effects | Xenograft Model Antitumor Assays | Phosphotransferases (Alcohol Group Acceptor) - antagonists & inhibitors | Sphingosine - analogs & derivatives | Animals | Protein Kinase Inhibitors - therapeutic use | Fibroblasts - drug effects | Melanoma - drug therapy | Cell Line, Tumor | Resting Phase, Cell Cycle - drug effects | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | G1 Phase Cell Cycle Checkpoints - drug effects | Staurosporine - pharmacology | RNA, Small Interfering - metabolism | Phosphates | Proteins | Cell death | Genes | Sphingosine | Development and progression | Health aspects | Index Medicus
Journal Article
BMB Reports, ISSN 1976-6696, 2014, Volume 47, Issue 5, p. 249
Polo-like kinase-1 (Plk1) belongs to a family of serine-threoninekinases and plays a critical role in mitotic progression. Plk1involves in the initiation of... 
DNA damage checkpoint | Polo-like kinase-1 | Cell cycle | p53
Journal Article
Journal Article
Medicinal Chemistry Research, ISSN 1054-2523, 8/2012, Volume 21, Issue 8, pp. 1912 - 1920
We have performed docking of imidazo[1,2-a]pyrazines complexed with checkpoint kinase1 (Chk1) to better understand the structural requirements and preferred... 
Biochemistry, general | Checkpoint kinase-1 inhibitors | Biomedicine | Quantitative structure–activity relationships | Pharmacology/Toxicology | Molecular docking | Cell Biology | CoMSIA | Quantitative structure-activity relationships | DESIGN | CHEMISTRY, MEDICINAL | PEPTIDES | IDENTIFICATION | DERIVATIVES | CANCER | PREDICTION
Journal Article